Wall Street analysts predict that SeaSpine Holdings Corp (NASDAQ:SPNE) will announce ($0.37) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for SeaSpine’s earnings, with estimates ranging from ($0.49) to ($0.25). SeaSpine posted earnings of ($0.56) per share during the same quarter last year, which would suggest a positive year over year growth rate of 33.9%. The company is expected to announce its next earnings report on Wednesday, February 27th.

According to Zacks, analysts expect that SeaSpine will report full year earnings of ($2.07) per share for the current fiscal year, with EPS estimates ranging from ($2.18) to ($1.80). For the next financial year, analysts anticipate that the business will post earnings of ($1.58) per share, with EPS estimates ranging from ($1.95) to ($1.30). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for SeaSpine.

SeaSpine (NASDAQ:SPNE) last issued its quarterly earnings results on Tuesday, November 6th. The medical equipment provider reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.12). The firm had revenue of $35.83 million for the quarter, compared to the consensus estimate of $35.56 million. SeaSpine had a negative net margin of 22.60% and a negative return on equity of 30.81%.

Several equities analysts recently commented on SPNE shares. BidaskClub upgraded shares of SeaSpine from a “hold” rating to a “buy” rating in a report on Saturday, October 27th. Zacks Investment Research downgraded shares of SeaSpine from a “buy” rating to a “hold” rating in a report on Friday, November 16th. ValuEngine upgraded shares of SeaSpine from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 11th. LADENBURG THALM/SH SH set a $23.00 price target on shares of SeaSpine and gave the company a “buy” rating in a report on Wednesday, October 3rd. Finally, HC Wainwright set a $19.00 price target on shares of SeaSpine and gave the company a “buy” rating in a report on Thursday, November 8th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. SeaSpine presently has a consensus rating of “Buy” and an average price target of $20.17.

Shares of NASDAQ:SPNE opened at $17.80 on Friday. The stock has a market cap of $341.19 million, a P/E ratio of -6.90 and a beta of 0.23. SeaSpine has a 12 month low of $8.76 and a 12 month high of $20.75. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.31 and a current ratio of 2.91.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its stake in SeaSpine by 110.3% in the 2nd quarter. BlackRock Inc. now owns 936,948 shares of the medical equipment provider’s stock worth $11,826,000 after acquiring an additional 491,379 shares in the last quarter. Novo Holdings A S grew its stake in SeaSpine by 0.8% in the 2nd quarter. Novo Holdings A S now owns 927,788 shares of the medical equipment provider’s stock worth $11,709,000 after acquiring an additional 7,408 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in SeaSpine by 8.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 620,561 shares of the medical equipment provider’s stock worth $9,656,000 after acquiring an additional 46,890 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in SeaSpine by 11.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 582,148 shares of the medical equipment provider’s stock worth $9,058,000 after acquiring an additional 58,612 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in SeaSpine by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 546,670 shares of the medical equipment provider’s stock worth $8,506,000 after acquiring an additional 31,726 shares in the last quarter. Institutional investors and hedge funds own 42.79% of the company’s stock.

About SeaSpine

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine.

See Also: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on SeaSpine (SPNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SeaSpine (NASDAQ:SPNE)

Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.